1
|
Parent H, Ferranti A, Niswender C. Trofinetide: a pioneering treatment for Rett syndrome. Trends Pharmacol Sci 2023; 44:740-741. [PMID: 37460385 PMCID: PMC10529922 DOI: 10.1016/j.tips.2023.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 06/23/2023] [Accepted: 06/23/2023] [Indexed: 08/09/2023]
Affiliation(s)
- Harrison Parent
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA
| | - Anthony Ferranti
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA
| | - Colleen Niswender
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA; Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, TN, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
| |
Collapse
|
5
|
Acher F, Battaglia G, Bräuner-Osborne H, Conn PJ, Duvoisin R, Ferraguti F, Flor PJ, Goudet C, Gregory KJ, Hampson D, Johnson MP, Kubo Y, Monn J, Nakanishi S, Nicoletti F, Niswender C, Pin JP, Rondard P, Schoepp DD, Shigemoto R, Tateyama M. Metabotropic glutamate receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. ACTA ACUST UNITED AC 2019. [DOI: 10.2218/gtopdb/f40/2019.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Metabotropic glutamate (mGlu) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Metabotropic Glutamate Receptors [334]) are a family of G protein-coupled receptors activated by the neurotransmitter glutamate. The mGlu family is composed of eight members (named mGlu1 to mGlu8) which are divided in three groups based on similarities of agonist pharmacology, primary sequence and G protein coupling to effector: Group-I (mGlu1 and mGlu5), Group-II (mGlu2 and mGlu3) and Group-III (mGlu4, mGlu6, mGlu7 and mGlu8) (see Further reading).Structurally, mGlu are composed of three juxtaposed domains: a core G protein-activating seven-transmembrane domain (TM), common to all GPCRs, is linked via a rigid cysteine-rich domain (CRD) to the Venus Flytrap domain (VFTD), a large bi-lobed extracellular domain where glutamate binds. The structures of the VFTD of mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 have been solved [190, 262, 255, 386]. The structure of the 7 transmembrane (TM) domains of both mGlu1 and mGlu5 have been solved, and confirm a general helical organization similar to that of other GPCRs, although the helices appear more compacted [85, 415, 59]. mGlu form constitutive dimers crosslinked by a disulfide bridge. Recent studies revealed the possible formation of heterodimers between either group-I receptors, or within and between group-II and -III receptors [86]. Although well characterized in transfected cells, co-localization and specific pharmacological properties also suggest the existence of such heterodimers in the brain [422, 257]. The endogenous ligands of mGlu are L-glutamic acid, L-serine-O-phosphate, N-acetylaspartylglutamate (NAAG) and L-cysteine sulphinic acid. Group-I mGlu receptors may be activated by 3,5-DHPG and (S)-3HPG [29] and antagonized by (S)-hexylhomoibotenic acid [223]. Group-II mGlu receptors may be activated by LY389795 [256], LY379268 [256], eglumegad [337, 416], DCG-IV and (2R,3R)-APDC [338], and antagonised by eGlu [161] and LY307452 [408, 100]. Group-III mGlu receptors may be activated by L-AP4 and (R,S)-4-PPG [125]. An example of an antagonist selective for mGlu receptors is LY341495, which blocks mGlu2 and mGlu3 at low nanomolar concentrations, mGlu8 at high nanomolar concentrations, and mGlu4, mGlu5, and mGlu7 in the micromolar range [176]. In addition to orthosteric ligands that directly interact with the glutamate recognition site, allosteric modulators that bind within the TM domain have been described. Negative allosteric modulators are listed separately. The positive allosteric modulators most often act as ‘potentiators’ of an orthosteric agonist response, without significantly activating the receptor in the absence of agonist.
Collapse
|
6
|
Han C, Chatterjee A, Noetzel MJ, Panarese JD, Smith E, Chase P, Hodder P, Niswender C, Conn PJ, Lindsley CW, Stauffer SR. Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorg Med Chem Lett 2014; 25:384-8. [PMID: 25435150 DOI: 10.1016/j.bmcl.2014.11.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Revised: 10/29/2014] [Accepted: 11/03/2014] [Indexed: 12/18/2022]
Abstract
Results from a 2012 high-throughput screen of the NIH Molecular Libraries Small Molecule Repository (MLSMR) against the human muscarinic receptor subtype 1 (M1) for positive allosteric modulators is reported. A content-rich screen utilizing an intracellular calcium mobilization triple-addition protocol allowed for assessment of all three modes of pharmacology at M1, including agonist, positive allosteric modulator, and antagonist activities in a single screening platform. We disclose a dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one hit (DBPQ, CID 915409) and examine N-benzyl pharmacophore/SAR relationships versus previously reported quinolin-3(5H)-ones and isatins, including ML137. SAR and consideration of recently reported crystal structures, homology modeling, and structure-function relationships using point mutations suggests a shared binding mode orientation at the putative common allosteric binding site directed by the pendant N-benzyl substructure.
Collapse
Affiliation(s)
- Changho Han
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - Arindam Chatterjee
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - Meredith J Noetzel
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - Joseph D Panarese
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - Emery Smith
- The Scripps Research Institutes Molecular Screening Center, Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida, USA
| | - Peter Chase
- The Scripps Research Institutes Molecular Screening Center, Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida, USA
| | | | - Colleen Niswender
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - P Jeffrey Conn
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA
| | - Craig W Lindsley
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA
| | - Shaun R Stauffer
- Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.
| |
Collapse
|
7
|
Grannan M, Bubser M, Bridges T, Gould R, Dencker Thorbek D, Daniels J, Noetzel M, Niswender C, Duggan M, Brandon N, Dunlop J, Wood M, Wess J, Wood M, Lindsley C, Conn P, Jones C. Effects of the M4 muscarinic receptor positive allosteric modulator VU0467154 on cognition and pyramidal cell firing properties in layer V of the mPFC (845.9). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.845.9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Michael Grannan
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Michael Bubser
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Thomas Bridges
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Robert Gould
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Ditte Dencker Thorbek
- Laboratory of NeuropsychiatryPsychiatric Centre Copenhagen Copenhagen University HospitalCopenhagenDenmark
| | - J Daniels
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Meredith Noetzel
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Colleen Niswender
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Mark Duggan
- Neuroscience Innovative Medicines AstraZenecaCambridgeMAUnited States
| | - Nicholas Brandon
- Neuroscience Innovative Medicines AstraZenecaCambridgeMAUnited States
| | - John Dunlop
- Neuroscience Innovative Medicines AstraZenecaCambridgeMAUnited States
| | - Michael Wood
- Neuroscience Innovative Medicines AstraZenecaCambridgeMAUnited States
| | - Jurgen Wess
- Laboratory of Bioorganic Chemistry, NIDDK NIHBETHESDAMDUnited States
| | - Michael Wood
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Craig Lindsley
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - P Conn
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| | - Carrie Jones
- Vanderbilt Center for Neuroscience Drug DiscoveryNashvilleTNUnited States
- Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN)NashvilleTNUnited States
- Pharmacology Vanderbilt UniversityNashvilleTNUnited States
| |
Collapse
|
8
|
Klein MT, Digby G, Niswender C, Tarr C, Poslusney M, Melancon B, Wood M, Lindsley C, Conn PJ. Novel Positive Allosteric Modulators Bias Acetylcholine Signaling at Human M
4
Muscarinic Receptors. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.1171.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Michael Thomas Klein
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Gregory Digby
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Colleen Niswender
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Christopher Tarr
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Michael Poslusney
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Bruce Melancon
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Michael Wood
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - Craig Lindsley
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| | - P. Jeffrey Conn
- Vanderbilt Center for Neuroscience Drug DiscoveryVanderbilt University Medical CenterNashvilleTN
| |
Collapse
|
9
|
Niswender C, Hopkins C, Jones C, Thompson A, Engers D, Williams R, Zhou S, Salovich J, Cheung YY, Gogliotti R, Gentry P, Johnson K, Jadhav S, Menon U, Zamorano R, Days E, Lindsley C, Weaver C, Conn P. P2.105 The development of positive allosteric modulators of mGluR4 for the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70456-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|